EUVIMEDEUVIMED entdecken
Crossref

Pediatric Extreme Thrombocytosis: Etiology, Management, and Outcomes

Adina Lashansky, Evgeny Grishin iD, Ivan Budnik, Orly Efros, Amos Toren, Sarina Levy-Mendelovich, Gili Kenet, Hana Golan, Assaf Arie Barg iD

Pediatric Blood & Cancer · 2025-10 · 72 (10)

DOI: 10.1002/pbc.31893 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Blood & Cancer, online erschienen am 02.07.2025. Verfasst von Adina Lashansky und 8 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicinal and Health Sciences, Tel Aviv University, Tel Aviv, Israel. Hauptthemen laut MEDLINE: Thrombocytosis, Thrombosis. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 22 Literaturangaben. Gefördert von: ASC therapeutics, Bayer, Biomarine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objective Extreme thrombocytosis (EXT) is defined as a platelet count >1000×10 9 /L. The aim of the current study was to evaluate the etiology, management, and outcome of pediatric patients with EXT, focusing on thrombotic complications. Study design We conducted a retrospective study at a large tertiary center, examining cases of pediatric EXT identified from electronic medical records over a 5‐year period. Patient demographics, clinical characteristics, and laboratory data were reviewed. Additionally, the underlying etiology was documented for each case, and follow‐up information was analyzed, including platelet count trends and thrombotic events within three months post‐EXT.

Results

Among 204 patients with EXT, 98% were secondary thrombocytosis, predominantly attributed to infections and inflammatory conditions. EXT prevailed among infants (median age 1.3 years), with 67% aged 3 years or younger. Thrombotic events occurred in 10 cases (4.9%), primarily related to central venous lines or other risk factors rather than elevated platelet counts alone. Aspirin prophylaxis was uncommon, administered in 14% of patients, mainly in those with existing comorbidities.

Conclusions

Secondary EXT in pediatric patients is commonly associated with infections and persists for up to 2 months in many cases. While EXT alone may not significantly increase thrombotic risk, it may contribute to risk in patients with additional predisposing factors, such as central venous line. Further prospective studies are warranted to clarify thrombotic risk in children with EXT and evaluate the potential benefit of antithrombotic prophylaxis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ThrombocytosisThrombosisHumansInfantFemaleMaleChild, PreschoolRetrospective StudiesChildAdolescentFollow-Up StudiesRisk FactorsInfant, NewbornPrognosisPlatelet Count

Stichwörter der Autor:innen

antithrombotic therapyextreme thrombocytosispediatricssecondary thrombocytosis

Autor:innen und Institutionen

  • Faculty of Medicinal and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
  • The Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Tel Hashomer, Israel.
  • Department of Internal Medicine, Division of Hematology/Oncology, University of Iowa, Iowa City, Iowa, USA.
  • Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.
  • Division of Pediatric Hematology and Oncology, The Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Tel Hashomer, Israel.
  • National Hemophilia Center, Coagulation Unit and Amalia Biron Research Institute of Thrombosis and Hemostasis, Sheba Medical Center, Ramat Gan, Israel.

ORCID-Profile: Evgeny Grishin, Assaf Arie Barg

Förderung

  • ASC therapeutics
  • Bayer
  • Biomarine
  • Novonordisk
  • Pfizer
  • Roche
  • Sanofi-Genzyme
  • Sobi

Zitieren

APA

Lashansky, A., Grishin, E., Budnik, I., Efros, O., Toren, A., Levy-Mendelovich, S., Kenet, G., Golan, H., & Barg, A. A. (2025). Pediatric Extreme Thrombocytosis: Etiology, Management, and Outcomes. Pediatric Blood & Cancer, 72(10). https://doi.org/10.1002/pbc.31893

Vancouver

Lashansky A, Grishin E, Budnik I, Efros O, Toren A, Levy-Mendelovich S, et al. Pediatric Extreme Thrombocytosis: Etiology, Management, and Outcomes. Pediatric Blood & Cancer. 2025;72(10). doi:10.1002/pbc.31893

BibTeX
@article{Lashansky2025,
  author = {Lashansky, Adina and Grishin, Evgeny and Budnik, Ivan and Efros, Orly and Toren, Amos and Levy-Mendelovich, Sarina and Kenet, Gili and Golan, Hana and Barg, Assaf Arie},
  title = {Pediatric Extreme Thrombocytosis: Etiology, Management, and Outcomes},
  journal = {Pediatric Blood & Cancer},
  year = {2025},
  volume = {72},
  number = {10},
  doi = {10.1002/pbc.31893}
}
Kostenlos starten →